Clinical Trial Update: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

View source ↗

Summary

A clinical trial update indicates the Nodify XL2 classifier utility study for evaluating low to moderate risk lung nodules is currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solitary Pulmonary Nodule

Snippet

Sponsor: Biodesix, Inc. | Conditions: Nodule Solitary Pulmonary, Non-small Cell Carcinoma | Status: ACTIVE_NOT_RECRUITING